WO2008096826A1 - 自己免疫疾患予防剤 - Google Patents

自己免疫疾患予防剤 Download PDF

Info

Publication number
WO2008096826A1
WO2008096826A1 PCT/JP2008/052057 JP2008052057W WO2008096826A1 WO 2008096826 A1 WO2008096826 A1 WO 2008096826A1 JP 2008052057 W JP2008052057 W JP 2008052057W WO 2008096826 A1 WO2008096826 A1 WO 2008096826A1
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune disease
prophylactic agent
taken
prevented
lactoperoxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/052057
Other languages
English (en)
French (fr)
Inventor
Hiroshi Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snow Brand Milk Products Co Ltd
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Priority to AU2008212212A priority Critical patent/AU2008212212A1/en
Priority to US12/525,882 priority patent/US20100316621A1/en
Priority to EP08710936A priority patent/EP2119445A4/en
Priority to KR1020097017223A priority patent/KR20090108088A/ko
Priority to CN2008800042933A priority patent/CN101631555B/zh
Priority to CA002677233A priority patent/CA2677233A1/en
Publication of WO2008096826A1 publication Critical patent/WO2008096826A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

　乳由来の塩基性タンパク質画分、ラクトパーオキシダーゼ、及びラクトフェリンを有効成分とする自己免疫疾患予防剤。日常的に摂取でき、長期にわたって摂取しても安全性が高く、従来の方法では有効に予防あるいは治療できなかった１型糖尿病や関節リウマチ等の自己免疫疾患を予防することができる。
PCT/JP2008/052057 2007-02-08 2008-02-07 自己免疫疾患予防剤 Ceased WO2008096826A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2008212212A AU2008212212A1 (en) 2007-02-08 2008-02-07 Prophylactic agent for autoimmune disease
US12/525,882 US20100316621A1 (en) 2007-02-08 2008-02-07 Prophylatic agent for autoimmune disease
EP08710936A EP2119445A4 (en) 2007-02-08 2008-02-07 PROPHYLACTIC AGENT FOR AUTOIMMUNE DISEASE
KR1020097017223A KR20090108088A (ko) 2007-02-08 2008-02-07 자기면역질환 예방제
CN2008800042933A CN101631555B (zh) 2007-02-08 2008-02-07 自身免疫病预防剂
CA002677233A CA2677233A1 (en) 2007-02-08 2008-02-07 Prophylactic agent for autoimmune disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-028809 2007-02-08
JP2007028809A JP2008189637A (ja) 2007-02-08 2007-02-08 自己免疫疾患予防剤

Publications (1)

Publication Number Publication Date
WO2008096826A1 true WO2008096826A1 (ja) 2008-08-14

Family

ID=39681730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052057 Ceased WO2008096826A1 (ja) 2007-02-08 2008-02-07 自己免疫疾患予防剤

Country Status (8)

Country Link
US (1) US20100316621A1 (ja)
EP (1) EP2119445A4 (ja)
JP (1) JP2008189637A (ja)
KR (1) KR20090108088A (ja)
CN (1) CN101631555B (ja)
AU (1) AU2008212212A1 (ja)
CA (1) CA2677233A1 (ja)
WO (1) WO2008096826A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
CN105101989B (zh) 2013-04-09 2019-10-18 加贺谷伸治 白细胞的细胞外诱捕网形成的抑制剂
KR101583734B1 (ko) 2014-09-01 2016-01-08 강원대학교 산학협력단 락토페린 및 레티노산을 함유하는 면역질환 예방 또는 치료용 조성물
JPWO2016056665A1 (ja) * 2014-10-08 2017-08-10 学校法人慶應義塾 白血球の細胞外トラップ形成の阻害剤
JP6941417B2 (ja) * 2016-02-04 2021-09-29 雪印メグミルク株式会社 軟骨機能改善剤

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61246198A (ja) 1985-02-07 1986-11-01 オレオフイナ・ソシエテ・アノニム 蛋白の精製法
JPS63255300A (ja) 1987-04-10 1988-10-21 Snow Brand Milk Prod Co Ltd 硫酸エステル化物を用いて乳からラクトフエリンを分離、精製する方法
JPS6486839A (en) 1987-06-19 1989-03-31 Entamonto Sa Method for selectively extracting metal protein from whey
JPH03109400A (ja) 1989-09-22 1991-05-09 Snow Brand Milk Prod Co Ltd 鉄結合性蛋白質を分離、精製し、採取する方法
JPH05186368A (ja) * 1992-01-08 1993-07-27 Santen Pharmaceut Co Ltd 抗リウマチ剤
JPH05202098A (ja) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd 乳質原料から生理活性物質の製造法
US5268170A (en) 1986-09-09 1993-12-07 Yeda Research And Development Co., Ltd. Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions
US5354691A (en) 1987-12-22 1994-10-11 De Staat Der Nederlanden Vertegenwoordigd Voor De Minister Van Welzijn, Volksgezondheid En Cultuur Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions
JPH08151331A (ja) * 1994-09-30 1996-06-11 Snow Brand Milk Prod Co Ltd 骨強化剤
US5578303A (en) 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
JPH10279479A (ja) * 1997-04-04 1998-10-20 Sagami Chem Res Center インターロイキン６の生産抑制剤
JPH11506601A (ja) * 1995-06-07 1999-06-15 ジェン−プローブ・インコーポレーテッド サイトカインシグナル伝達物質ｇｐ１３０ｍＲＮＡに特異的なオリゴヌクレオチド
WO2004073733A1 (ja) * 2003-02-24 2004-09-02 Morinaga Milk Industry Co., Ltd. インターロイキン−６産生抑制剤
WO2004103285A2 (en) * 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
US20060040025A1 (en) * 2002-07-02 2006-02-23 Jerome Souppe Milk protein isolate and method for preparing same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312369D0 (en) * 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5674995A (en) * 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5747470A (en) * 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
NL1005037C2 (nl) * 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CN1114618C (zh) * 2000-05-19 2003-07-16 程伶辉 三价铬复合物、其乳制品及其制造方法
DE60335665D1 (de) * 2003-05-07 2011-02-17 Snow Brand Milk Products Co Ltd Mittel zur förderung der hautkollagenproduktion
JP2008500304A (ja) * 2004-05-27 2008-01-10 カンピーナ ネーダーランド ホールディング ビー．ブイ． Ｄｐｐ−ｉｖ媒介症状の予防及び／又は治療用の薬剤製造のためのタンパク質加水分解物の使用
DK1831361T3 (da) * 2004-12-23 2012-05-14 Campina Nederland Holding Bv Proteinhydrolysat beriget med peptider, som inhiberer DPP-IV, og deres anvendelse
FR2889068B1 (fr) * 2005-07-29 2012-03-02 Cie Laitiere Europeenne Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
PL1800675T4 (pl) * 2005-12-23 2012-02-29 Nutricia Nv Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61246198A (ja) 1985-02-07 1986-11-01 オレオフイナ・ソシエテ・アノニム 蛋白の精製法
US5268170A (en) 1986-09-09 1993-12-07 Yeda Research And Development Co., Ltd. Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions
JPS63255300A (ja) 1987-04-10 1988-10-21 Snow Brand Milk Prod Co Ltd 硫酸エステル化物を用いて乳からラクトフエリンを分離、精製する方法
JPS6486839A (en) 1987-06-19 1989-03-31 Entamonto Sa Method for selectively extracting metal protein from whey
US5354691A (en) 1987-12-22 1994-10-11 De Staat Der Nederlanden Vertegenwoordigd Voor De Minister Van Welzijn, Volksgezondheid En Cultuur Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions
US5578303A (en) 1989-03-14 1996-11-26 Yeda Research And Development Co. Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
JPH03109400A (ja) 1989-09-22 1991-05-09 Snow Brand Milk Prod Co Ltd 鉄結合性蛋白質を分離、精製し、採取する方法
JPH05186368A (ja) * 1992-01-08 1993-07-27 Santen Pharmaceut Co Ltd 抗リウマチ剤
JPH05202098A (ja) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd 乳質原料から生理活性物質の製造法
JPH08151331A (ja) * 1994-09-30 1996-06-11 Snow Brand Milk Prod Co Ltd 骨強化剤
JPH11506601A (ja) * 1995-06-07 1999-06-15 ジェン−プローブ・インコーポレーテッド サイトカインシグナル伝達物質ｇｐ１３０ｍＲＮＡに特異的なオリゴヌクレオチド
JPH10279479A (ja) * 1997-04-04 1998-10-20 Sagami Chem Res Center インターロイキン６の生産抑制剤
US20060040025A1 (en) * 2002-07-02 2006-02-23 Jerome Souppe Milk protein isolate and method for preparing same
WO2004073733A1 (ja) * 2003-02-24 2004-09-02 Morinaga Milk Industry Co., Ltd. インターロイキン−６産生抑制剤
WO2004103285A2 (en) * 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
BOHME ET AL., SCIENCE, vol. 249, 1990, pages 293 - 5
CASTANO; EISENBARTH, ANN. REV. IMMUNOL., vol. 8, 1990, pages 647 - 79
ELIAS ET AL., EUR. J. IMMUNOL., vol. 25, 1995, pages 2851 - 2857
ELIAS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 1576 - 1580
ELIAS; COHEN, DIABETES, vol. 44, 1995, pages 1132 - 1138
HAJIME YASUHARA; SHINICHI KOBAYASHI: "Sequel to Development of Drugs", vol. 8, 1991, HIROKAWA-SHOTEN, LTD., pages: 7 - 18
HAMAGUCHI; LEITER, DIABETES, vol. 39, 1990, pages 415
HASKINS ET AL., SCIENCE, vol. 249, 1990, pages 1433 - 36
KAUFMEN ET AL., NATURE, vol. 366, 1993, pages 69 - 72
LIDER ET AL., SCIENCE, vol. 239, 1988, pages 181
MAKINO, S. ET AL., CURRENT TOPICS IN CLINICAL ANDEXPERIMENTAL ASPECTS OF DIABETES, 1985
MIYAZAKI ET AL., NATURE, vol. 345, 1990, pages 722 - 4
NAKANO ET AL., J. EXP. MED., vol. 173, 1991, pages 1091 - 7
NISHIMOTO ET AL., NATURE, vol. 328, 1987, pages 432 - 4
NISHIMURA A. ET AL.: "Increase in splenic production of interleukin 6 and interleukin 1 prior to development of diabetes mellitus in non-obese diabetic mice", ACTA MED. KINKI UNIV., vol. 23, no. 1-2, 1998, pages 31 - 39, XP008110368 *
RAPOPORT ET AL., J. EXP. MED., vol. 178, 1993, pages 87
REICH ET AL., NATURE, vol. 341, 1993, pages 326 - 9
SAISHIN IGAKU, vol. 61, no. 5, 2006, pages 917 - 1009
SERREZE ET AL., J. IMMUNOL., vol. 140, 1988, pages 3801
SERREZE ET AL., J. IMMUNOL., vol. 150, 1993, pages 2534
SERREZE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 9625
SHINNICK ET AL., INFECT. IMMUN., vol. 55, 1987, pages 1932 - 1935
SINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 9566 - 70
SLATTERY ET AL., NATURE, vol. 345, 1990, pages 724 - 6
SOLIMENA; DE CAMILLI, NATURE MEDICINE, vol. 2, 1996, pages 1311
TAN ET AL., J. EXP. MED., vol. 182, 1995, pages 87 - 97
TISCH ET AL., NATURE, vol. 366, 1993, pages 72 - 5
TODD, J.A., IMMUNOL. TODAY, vol. 11, 1990, pages 122 - 9
ZIPRIS ET AL., J. IMMUNOL., vol. 146, 1991, pages 3763

Also Published As

Publication number Publication date
US20100316621A1 (en) 2010-12-16
EP2119445A4 (en) 2012-02-01
KR20090108088A (ko) 2009-10-14
CN101631555A (zh) 2010-01-20
CN101631555B (zh) 2013-04-03
JP2008189637A (ja) 2008-08-21
CA2677233A1 (en) 2008-08-14
AU2008212212A1 (en) 2008-08-14
EP2119445A1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
FitzGerald et al. Enzymatic debittering of food protein hydrolysates
WO2007142542A3 (en) Cationic milk proteins for treating mastitis
WO2005119627A3 (en) Personal nutrition control devices
Seo et al. Optimization of hydrolysis conditions for bovine plasma protein using response surface methodology
WO2007009065A3 (en) Methods of treating autoimmune disease using humanized anti-cd16a antibodies
WO2001037850A3 (en) Use of a milk protein hydrolysate in the treatment of diabetes
WO2005007818A8 (en) Exo-specific amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof
WO2009092961A3 (fr) Ensemble de stabilisation intervertebrale pour arthrodese comprenant un corps de cage a impaction, et son ancillaire de pose
WO2005121331A3 (en) Truncated galnact2 polypeptides and nucleic acids
WO2004048517A3 (en) Method for reducing or preventing modification of a polypeptide in solution
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
Assem et al. Proteolysis and antioxidant activity of peptic, tryptic and chymotryptic hydrolysates of cow, buffalo, goat and camel caseins
WO2007139997A3 (en) Methods for site-specific pegylation
WO2006015258A3 (en) Methods and compositions related to argonaute proteins
WO2007109681A3 (en) Compositions and methods for enhancing vasodilation
WO2012046945A3 (ko) 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물
WO2009069738A1 (ja) 風味改良剤
WO2005045428A3 (en) Methods and compositions for modulating apoptosis
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
WO2008071755A3 (fr) Peptides derives de la caseine ayant une activité anxiolytique
Wasswa et al. Optimization of the production of hydrolysates from grass carp (Ctenopharyngodon idella) skin using alcalase
WO2004037168A3 (en) Treatment of pancreatitis with amylin
WO2005062893A3 (en) Anti-cd52 antibody treatment for diabetes
WO2002096398A3 (de) Arzneimittel enthaltend einen effektor des glutathionmetabolismus zussammen mit $g(a)-liponsäure im rahmen der behandlung des diabetes mellitus
WO2009057282A1 (ja) 骨吸収抑制用食品素材

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880004293.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710936

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008212212

Country of ref document: AU

Ref document number: 2677233

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008710936

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 578830

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12525882

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097017222

Country of ref document: KR

Ref document number: 1020097017223

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2008212212

Country of ref document: AU

Date of ref document: 20080207

Kind code of ref document: A